Markets

Onconova Therapeutics, Inc. (ONTX): How Do the Books Stack Up?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 33.22M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ONTX, the company currently has 7.26 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 8.62 million in total assets, balanced by 15.49 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Onconova Therapeutics, Inc. (ONTX) saw -5.51 million in free cash flow last quarter, representing a quarterly net change in cash of 3.24 million. Perhaps most importantly where cash movements are concerned, the company saw about -5.51 million in net operating cash flow.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 564,000 in total revenues. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the ONTX saw sales decline by 0.00.



But what about the bottom line? After all, that’s what really matters in the end. Onconova Therapeutics, Inc. (ONTX) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 15.14 million, this means overall earnings per share of -0.34. Note, this compares with a consensus analyst forecast of -0.06 in earnings per share for its next fiscal quarterly report.

Is Onconova Therapeutics, Inc. (NASDAQ:ONTX) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.32 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Onconova Therapeutics, Inc..

Previous ArticleNext Article

Related Post

Taking a Look at the Operational Data for Comcast ... Comcast Corporation (NASDAQ:CMCSA) is one of the active stocks and its unusual movement is raising eyebrows among traders. Now trading with a market v...
Technical Indicators Turn Indifferent For Marathon... Marathon Oil Corporation (NYSE:MRO) gained 1.35% in the first business day of September, going up from its prior closing price of $11.12 to $11.27, an...
Checking Out the Fundamental Data for Helios and M... It is interesting to note that Helios and Matheson Analytics Inc. (NASDAQ:HMNY) is active and made a solid movement in the last trading day. Now tradi...
BRF S.A. (BRFS): Interesting Series Of Development... BRF S.A. (NYSE:BRFS) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value of 5.82B, t...
For Range Resources Corporation (RRC), It May Be A... Range Resources Corporation (NYSE:RRC) is an interesting stock at present. Now trading with a market value of 4.25B, the company has a mix of catalyst...